Avantor (AVTR) to Release Quarterly Earnings on Friday

Avantor (NYSE:AVTR - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Friday, April 25th. Analysts expect the company to announce earnings of $0.23 per share and revenue of $1.61 billion for the quarter.

Avantor (NYSE:AVTR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same period in the prior year, the firm posted $0.22 earnings per share. On average, analysts expect Avantor to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avantor Trading Up 1.5 %

Shares of NYSE:AVTR traded up $0.23 during midday trading on Tuesday, reaching $15.19. The company's stock had a trading volume of 4,104,746 shares, compared to its average volume of 6,939,179. The firm has a market cap of $10.35 billion, a price-to-earnings ratio of 14.59, a price-to-earnings-growth ratio of 1.55 and a beta of 1.24. The business has a 50 day moving average price of $16.26 and a 200 day moving average price of $20.00. Avantor has a 1 year low of $13.80 and a 1 year high of $28.00. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AVTR. Citigroup decreased their target price on shares of Avantor from $22.00 to $18.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Stifel Nicolaus lowered their price objective on shares of Avantor from $28.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, February 10th. Wells Fargo & Company cut their target price on Avantor from $25.00 to $22.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Royal Bank of Canada lowered their price target on Avantor from $33.00 to $31.00 and set an "outperform" rating for the company in a research report on Monday, February 10th. Finally, UBS Group restated a "neutral" rating and issued a $25.00 price objective (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Avantor has an average rating of "Moderate Buy" and an average target price of $24.82.

Insider Transactions at Avantor

In other Avantor news, CAO Steven W. Eck sold 4,907 shares of the business's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total transaction of $86,019.71. Following the completion of the sale, the chief accounting officer now owns 40,604 shares in the company, valued at $711,788.12. The trade was a 10.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP James Bramwell sold 3,758 shares of the firm's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $17.53, for a total transaction of $65,877.74. Following the completion of the transaction, the executive vice president now owns 87,379 shares in the company, valued at approximately $1,531,753.87. The trade was a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company's stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.